Delivra Health Brands Inc.
Volatile Quarter, Strong Fundamentals Remain Intact
Published: 12/3/2024
Author: FRC Analysts
Sector: Healthcare | Industry: Drug Manufacturers-Specialty & Generic
Ticker Symbols:DHBUF - NASDAQ 🔹DHB.V - TSX 🔹
Rating and Key Data
| Metrics | Value |
|---|---|
| Current Price | CAD $0.02 |
| Fair Value | CAD $0.09 |
| Risk | 3 |
| 52 Week Range | CAD $0.015-0.055 |
| Shares O/S (M) | 313 |
| Market Cap. (M) | CAD $6 |
| Current Yield (%) | N/A |
| P/E (forward) | N/A |
| P/B | 1.3 |
Already a subscriber?
Want to know the fair value of the stock?
Subscribe for free to get exclusive insights and data.
Report Highlights
- Q1-FY2025 (ended September 2024) revenue declined 14% YoY, coming in 22% below our estimate. Management attributed this decline to a timing mismatch in sales orders from large customers. Note that Q1-FY2024 revenue was unusually high due to the same issue, with more orders coming in that quarter, leading to a steep drop in the following quarter. We anticipate a spike in Q2-FY2025 revenue as the orders missed in Q1 materialize.
- Historically, quarterly revenue has been volatile (as shown on page 3). In some previous Q1s, revenue declined YoY, but full-year results still showed growth. Management is confident they will be able to report YoY revenue growth this year. The company has achieved YoY revenue growth in each of the past four years: 2% in both FY2021 and FY2022, 20% in FY2023, and 26% in FY2024.
- The company’s products are available at 30k+ distribution points, including established retail/pharmacy chains such as Shoppers Drug Mart, Walmart (NYSE: WMT), and Kroger (NYSE: K
